| Year |
Citation |
Score |
| 2019 |
Goldstein JT, Berger AC, Strathdee CA, Meyerson M. Abstract 1026: Oncogenic alterations in FGFR3 and ERBB2 lead to ligand-independent activation of PPARG in bladder cancer Cancer Research. 79: 1026-1026. DOI: 10.1158/1538-7445.Am2019-1026 |
0.373 |
|
| 2018 |
Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS, Ivan AP, Buchumenski I, Berger AC, Goldstein JT, Cherniack AD, Vazquez F, Tsherniak A, Levanon EY, Hahn WC, et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nature Communications. 9: 5450. PMID 30575730 DOI: 10.1038/S41467-018-07824-4 |
0.301 |
|
| 2017 |
Goldstein JT, Berger AC, Shih J, Duke FF, Furst L, Kwiatkowski DJ, Cherniack AD, Meyerson M, Strathdee CA. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Research. PMID 28923856 DOI: 10.1158/0008-5472.Can-17-1701 |
0.327 |
|
| 2017 |
Goldstein JT, Strathdee C, Duke F, Shih J, Meyerson M. Abstract 3627: Validation of PPARG and RXRA as drivers of bladder cancer Cancer Research. 77: 3627-3627. DOI: 10.1158/1538-7445.Am2017-3627 |
0.309 |
|
| 2012 |
Huang H, Acquaviva L, Berry V, Bregman H, Chakka N, O'Connor A, DiMauro EF, Dovey J, Epstein O, Grubinska B, Goldstein J, Gunaydin H, Hua Z, Huang X, Huang L, et al. Structure-Based Design of Potent and Selective CK1γ Inhibitors. Acs Medicinal Chemistry Letters. 3: 1059-64. PMID 24900428 DOI: 10.1021/Ml300278F |
0.302 |
|
| 2003 |
Goldstein JT, Dobrzyn A, Clagett-Dame M, Pike JW, DeLuca HF. Isolation and characterization of unsaturated fatty acids as natural ligands for the retinoid-X receptor. Archives of Biochemistry and Biophysics. 420: 185-93. PMID 14622989 DOI: 10.1016/J.Abb.2003.09.034 |
0.374 |
|
| Show low-probability matches. |